Neuralink, the brain-implant company founded by Elon Musk, has raised US$600 million in funding. This brings its valuation to US$9 billion, according to sources familiar with the matter.

This funding follows a valuation of US$3.5 billion in late 2023, as reported by Pitchbook.

The company has implanted brain chips in three patients, including a man with ALS.

He demonstrated the device’s capabilities by speaking through the chip in a video shared on Musk’s platform, X, last month.

🔗 Source: Semafor

🧠 Food for thought

1️⃣ Neurotechnology funding has shifted dramatically from government to private capital

Brain-computer interface research was historically dominated by government funding, but venture capital now leads the way in this sector.

Neuralink’s rapid funding progression illustrates this shift, from a modest US$27 million raised in 2017 to now $600 million in a single round, bringing their total funding to well over US$1 billion 1.

Private investment in neurotechnology has outpaced public funding, with companies like Paradromics and Synchron also attracting significant venture capital despite being at earlier clinical stages 1.

This capital influx enables more ambitious technical approaches that were previously difficult under the constraints of government grant cycles, potentially accelerating development timelines for medical applications.

2️⃣ Brain implant technology faces a lengthy path from demonstration to commercial viability

Despite the impressive demonstrations with Neuralink’s first patients, significant barriers remain before commercial availability is possible.

MIT Technology Review specifically noted that despite the ongoing human trials, the product is “not yet ready to be released commercially,” highlighting the gap between proof-of-concept and market-ready technology 2.

Historical context shows that brain implant development is exceptionally challenging. In 2017, experts estimated development costs could reach US$200 million with extensive testing requirements, a figure Neuralink has now far exceeded 3.

The Neuralink timeline shows the methodical progression required, beginning with animal trials (achieving 87% success in wire placement), before carefully moving to the current limited human trials 4.